|
|
News Breaks | | | | November 4, 2012 | | 01:43 EDT |  | VRX, GILD, ABT | Vertex Pharmaceuticals offers investors few catalysts, Barron's says
Vertex Pharmaceuticals (VRX) was once a Wall Street darling, but sales of its blockbuster hepatitis C drug, Incivek, are falling. And as Incivek sales keep falling, many worry that Vertex may start losing money next year. Q3 results disappointed investors. And shares sank Friday, as Goldman Sachs analyst Terence Flynn downgraded the stock to a Sell. The worry is that experimental cystic fibrosis drugs now in development may not prove to be potent enough to help patients. Also, Gilead Sciences (GILD) and Abbott Laboratories (ABT) have rival hepatitis C drugs in phase three trials, which Vertex won't start until 2014. Barron's contends that Vertex faces challenges that make the stock unattractive even at a marked-down price. Reference Link | |
|
News For VRX;ABT;GILD From The Last 14 Days Check below for free stories on VRX;ABT;GILD the last two weeks. |
|
|
| May 24, 2013 | | 13:18 EDT |  | VRX | On The Fly: Midday Wrap
 Subscribe for More Information | | | 12:33 EDT |  | VRX | Valeant calls active, near deal to buy Bausch & Lomb
Subscribe for More Information | | | 12:30 EDT | | VRX | Valeant near deal to acquire Bausch & Lomb for $9B, WSJ reports
Bausch & Lomb is close to a deal to sell itself to Valeant for $9B in a deal that could be done as early as next week, reports The Wall Street Journal, citing people familiar with the matter. Shares of Valeant are trading sharply higher following the report, up $8.43, or 11.29%, to $83.10.Reference Link | | | 12:08 EDT |  | VRX | Valeant up 11% after Dow says near deal to buy Bausch & Lomb
Subscribe for More Information | | | 12:07 EDT | | VRX | Bausch & Lomb near deal to sell itself to Valeant for around $9B, Dow says
| | | 07:20 EDT |  | GILD | Celgene, Gilead, and Biogen could go much higher, says Bernstein
Subscribe for More Information | | | May 23, 2013 | | 10:27 EDT |  | GILD | Gilead has a conference call hosted by JPMorgan
Subscribe for More Information | | | May 22, 2013 | | 07:28 EDT | | ABT | UBS to host a conference
Global Healthcare Services Conference is being held in New York on May 20-22 with webcasted company presentations to begin on May 22 at 8 am; not all company presentations may be webcasted. Webcast Link | | | May 21, 2013 | | 16:51 EDT | | GILD | Gilead's sofosbuvir gets EMA validation, now under assessment
Subscribe for More Information | | | 08:03 EDT | | ABT | Abbott announces CE Mark for coronary drug eluting stent
Subscribe for More Information | | | | May 20, 2013 | | 10:11 EDT |  | ABT | On The Fly: Analyst Upgrade Summary
Subscribe for More Information | | | 07:34 EDT | | GILD | UBS to host a conference
Subscribe for More Information | | | 06:01 EDT | | ABT | Abbott upgraded to Buy from Neutral at Goldman
Goldman upgraded Abbott to reflect accelerating growth driven by emerging markets, better growth and product mix, new product launches, and market share gains. Price target raised to $44 from $38. | | | May 17, 2013 | | 14:48 EDT | | VRX | Actavis may bid for Warner Chilcott to ward off takeover, Reuters says
Subscribe for More Information | | | 13:56 EDT | | VRX | Actavis may purchase Warner Chilcott as takeover defense, Reuters reports
Over past few weeks, Actavis (ACT) has "spurned approaches" from Valeant (VRX) and Mylan (MYL), and has instead pursued a bid for Warner Chilcott (WCRX), according to Reuters, citing people familiar with the situation. | | | May 16, 2013 | | 11:50 EDT | | GILD | Celgene, Gilead lower after new data published at ASCO
Subscribe for More Information | | | May 15, 2013 | | 19:37 EDT | | VRX | Novartis weighing Actavis bid, WSJ reports
Subscribe for More Information | | | 18:32 EDT | | GILD | Gilead announces response data from Phase 2 study of Idelalisib
Subscribe for More Information | | | May 14, 2013 | | 17:48 EDT | | VRX | Lone Pine gives quarterly update on stakes
NEW STAKES: Valeant Pharmaceuticals (VRX), Virgin Media (VMED), Thermo Fisher Scientific (TMO), CME Group (CME), and Liberty Media (LMCA). INCREASED STAKES: Mead Johnson Nutrition (MJN), News Corp (NWSA), Intuitive Surgical (ISRG), Monsanto (MON), and Qualcomm (QCOM). DECREASED STAKES: Cognizant Technology Solutions (CTSH), Equinix (EQIX), Ralph Lauren (RL), Disney (DIS), and Oceaneering International (OII). LIQUIDATED STAKES: Facebook (FB), Crown Castle (CCI), Accretive Health (AH), Informatica (INFA), and NetEase (NTES). | | | 13:55 EDT | | VRX | Actavis weighing over $5B bid for Warner Chilcott, snubbed Mylan, Bloomberg says
Subscribe for More Information | | |
|
|
|
|
|
|
